The MAGIC-Cell series of studies were the earliest clinical trials to explore the use of G-CSF to mobilize stem cells and repair damaged myocardium following MI (Table 4). In the early phase of the study, 27 subjects were enrolled and randomly divided into three groups: the cell infusion group (n = 10), the G-CSF monotherapy group (n = 10), and the control group (n = 7). This evidence concerns the gene CSF3 and myocardial infarction.